Literature DB >> 18261715

Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia.

Mihály Hajós1, William E Hoffmann, Bernát Kocsis.   

Abstract

BACKGROUND: Impaired auditory gating and abnormal neuronal synchrony are indicators of dysfunctional information processing in schizophrenia patients and possible underlying mechanisms of their impaired sensory and cognitive functions. Because cannabinoid receptors and endocannabinoids have been linked to psychiatric disorders, including schizophrenia, the aim of this study was to evaluate the effects of cannabinoid-1 (CB1) receptor activation on sensory gating and neuronal oscillations in rats.
METHODS: Auditory sensory gating has been recorded from the hippocampus and entorhinal cortex (EC) in anesthetized rats. Neuronal network oscillations were recorded from the hippocampus, medial septum, EC, and medial prefrontal cortex in anesthetized and freely moving rats. Effects of systemic administration of CB1 receptor agonist CP-55940 were evaluated on these parameters.
RESULTS: CP-55940 significantly disrupted auditory gating both in the hippocampus and EC in anesthetized rats. Theta field potential oscillations were disrupted in the hippocampus and EC, with simultaneous interruption of theta-band oscillations of septal neurons. Administration of the CB1 receptor antagonist AM-251 reversed both the agonist-induced gating deficit and the diminished oscillations. In freely moving rats, CP-55940 significantly reduced theta and gamma power in the hippocampus, whereas in the EC, only gamma power was attenuated. However, novelty-induced theta and gamma activities were significantly diminished by CP-55940 in both the hippocampus and EC.
CONCLUSIONS: Our data indicate that activation of CB1 receptors interferes with neuronal network oscillations and impairs sensory gating function in the limbic circuitry, further supporting the connection between cannabis abuse and increased susceptibility of developing schizophrenia spectrum disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18261715     DOI: 10.1016/j.biopsych.2007.12.005

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  74 in total

1.  Reduced glutamate decarboxylase 65 protein within primary auditory cortex inhibitory boutons in schizophrenia.

Authors:  Caitlin E Moyer; Kristen M Delevich; Kenneth N Fish; Josephine K Asafu-Adjei; Allan R Sampson; Karl-Anton Dorph-Petersen; David A Lewis; Robert A Sweet
Journal:  Biol Psychiatry       Date:  2012-05-23       Impact factor: 13.382

2.  The effect of chronic cannabinoids on broadband EEG neural oscillations in humans.

Authors:  Patrick D Skosnik; Deepak C D'Souza; Adam B Steinmetz; Chad R Edwards; Jennifer M Vollmer; William P Hetrick; Brian F O'Donnell
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

3.  Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study.

Authors:  Michael Kiang; Bruce K Christensen; David L Streiner; Carolyn Roy; Iulia Patriciu; Robert B Zipursky
Journal:  Psychopharmacology (Berl)       Date:  2012-07-11       Impact factor: 4.530

4.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

5.  Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice.

Authors:  Sylvina M Raver; Sarah P Haughwout; Asaf Keller
Journal:  Neuropsychopharmacology       Date:  2013-07-04       Impact factor: 7.853

6.  Alterations to pre-pulse inhibition (PPI) in chronic cannabis users are secondary to sustained attention deficits.

Authors:  Kirsty Elizabeth Scholes; Mathew Thomas Martin-Iverson
Journal:  Psychopharmacology (Berl)       Date:  2009-10-09       Impact factor: 4.530

Review 7.  Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia.

Authors:  Michael J Gandal; J Christopher Edgar; Kerstin Klook; Steven J Siegel
Journal:  Neuropharmacology       Date:  2011-02-22       Impact factor: 5.250

8.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

9.  The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.

Authors:  Jose A Cortes-Briones; John D Cahill; Patrick D Skosnik; Daniel H Mathalon; Ashley Williams; R Andrew Sewell; Brian J Roach; Judith M Ford; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2015-03-30       Impact factor: 13.382

Review 10.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.